{"id":"fluticasone-125-formoterol-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1676","moleculeType":"Small molecule","molecularWeight":"538.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that suppresses inflammatory responses in the airways by binding to glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilatory effects for maintenance asthma and COPD control.","oneSentence":"Fluticasone/formoterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:38.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT02440009","phase":"PHASE2, PHASE3","title":"A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-05","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":191},{"nctId":"NCT03387241","phase":"PHASE3","title":"Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2017-06-02","conditions":"Asthma","enrollment":330},{"nctId":"NCT00563056","phase":"PHASE3","title":"An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2007-09","conditions":"Asthma Bronchiale","enrollment":227},{"nctId":"NCT01946620","phase":"PHASE3","title":"A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2013-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1767},{"nctId":"NCT01099722","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2010-04","conditions":"Asthma","enrollment":261},{"nctId":"NCT01621321","phase":"PHASE2, PHASE3","title":"Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2013-06","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":50},{"nctId":"NCT02195375","phase":"PHASE2, PHASE3","title":"Flutiform® Compared With Seretide® in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":923},{"nctId":"NCT01321827","phase":"PHASE2, PHASE3","title":"Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-04","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT02693769","phase":"PHASE2, PHASE3","title":"A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2016-07","conditions":"ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)","enrollment":2},{"nctId":"NCT02388373","phase":"PHASE4","title":"A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2014-07","conditions":"Asthma","enrollment":225},{"nctId":"NCT02415179","phase":"NA","title":"Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2015-05","conditions":"Asthma","enrollment":52},{"nctId":"NCT02403713","phase":"PHASE1","title":"A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2014-08","conditions":"Asthma","enrollment":125},{"nctId":"NCT00747318","phase":"PHASE3","title":"A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Asthma","enrollment":280},{"nctId":"NCT00830102","phase":"PHASE2","title":"Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2004-10","conditions":"Asthma","enrollment":64},{"nctId":"NCT00734292","phase":"PHASE2","title":"Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Mild to Moderate Asthma","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Flutiform 125"],"phase":"marketed","status":"active","brandName":"Fluticasone 125/formoterol 5","genericName":"Fluticasone 125/formoterol 5","companyName":"Research in Real-Life Ltd","companyId":"research-in-real-life-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone/formoterol is a combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and dilates airways to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}